Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Functional Pancreatic Neuroendocrine Tumor

Vanderbilt-Ingram Cancer CenterSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Functional Pancreatic Neuroendocrine Tumor cohort.

Asset / SponsorPhaseRating
Cediranib
Vanderbilt-Ingram Cancer Center
Phase 2B
LEUPROLIDE
M.D. Anderson Cancer Center
Phase 2B
Ribociclib
M.D. Anderson Cancer Center
Phase 2B
Letrozole
M.D. Anderson Cancer Center
Phase 2B
FULVESTRANT
M.D. Anderson Cancer Center
Phase 2B

View all 10 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →